• Company to also host virtual webcast with a cardiology business update

MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the third quarter on October 23 prior to the conference call.

The company will also host a virtual investor event on Wednesday, October 30, 2024, from 4:00 – 5:00 p.m. ET following Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). Joe Fitzgerald, executive vice president and president of Cardiology, Dr. Ken Stein, executive vice president and global chief medical officer, Lance Bates, executive vice president and president Interventional Cardiology Therapies (ICTx) and Dr. Janar Sathananthan, chief medical officer ICTx, will present a business update and answer questions from investors.

A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.  

CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
This email address is being protected from spambots. You need JavaScript enabled to view it.

Jon Monson
Investor Relations
+1 (508) 683-5450
This email address is being protected from spambots. You need JavaScript enabled to view it.